GSK's Shingrix Generates £1.278 Billion in First Three Quarters of 2019; China Launch Scheduled for 2020

Text | Baihuawen

On October 30, GSK announced its financial results for the first three quarters of 2019, reporting revenue of £24.855 billion, a 7% year-on-year increase at constant exchange rates. Revenue for the third quarter amounted to £9.385 billion, representing an 11% year-on-year growth.

In Q3 2019, GSK’s pharmaceuticals revenue was £4.531 billion, a year-on-year increase of 3%; vaccines revenue was £2.308 billion, a year-on-year increase of 15%; and consumer healthcare revenue was £2.526 billion, a year-on-year increase of 25%.

In May 2019, the shingles vaccine Shingrix was approved in China. However, as GSK planned to launch the product in China only in 2020, its performance in the Chinese market will be reflected in next year’s financial report. In its Q3 quarterly report released this time, GSK stated that the sales growth of Shingrix was primarily driven by the U.S. market. It is estimated that approximately 3 million people in China are affected by shingles each year.

GSK’s Core Product Sales in the First Three Quarters of 2019 (Billions of GBP)